TY - JOUR AU - Chen, W. AU - Zheng, R. AU - Baade, P. D. AU - Zhang, S. AU - Zeng, H. AU - Bray, F. PY - 2016 DA - 2016// TI - Cancer statistics in China, 2015 JO - CA Cancer J Clin VL - 66 UR - https://doi.org/10.3322/caac.21338 DO - 10.3322/caac.21338 ID - Chen2016 ER - TY - JOUR AU - Jusakul, A. AU - Cutcutache, I. AU - Yong, C. H. AU - Lim, J. Q. AU - Huang, M. N. AU - Padmanabhan, N. PY - 2017 DA - 2017// TI - Whole-genome and epigenomic landscapes of etiologically distinct subtypes of cholangiocarcinoma JO - Cancer Discov VL - 7 UR - https://doi.org/10.1158/2159-8290.CD-17-0368 DO - 10.1158/2159-8290.CD-17-0368 ID - Jusakul2017 ER - TY - JOUR AU - Razumilava, N. AU - Gores, G. J. PY - 2014 DA - 2014// TI - Cholangiocarcinoma JO - Lancet. VL - 383 UR - https://doi.org/10.1016/S0140-6736(13)61903-0 DO - 10.1016/S0140-6736(13)61903-0 ID - Razumilava2014 ER - TY - JOUR AU - Khan, S. A. AU - Taylor-Robinson, S. D. AU - Toledano, M. B. AU - Beck, A. AU - Elliott, P. AU - Thomas, H. C. PY - 2002 DA - 2002// TI - Changing international trends in mortality rates for liver, biliary and pancreatic tumours JO - J Hepatol VL - 37 UR - https://doi.org/10.1016/S0168-8278(02)00297-0 DO - 10.1016/S0168-8278(02)00297-0 ID - Khan2002 ER - TY - JOUR AU - Zhang, H. AU - Yang, T. AU - Wu, M. AU - Shen, F. PY - 2016 DA - 2016// TI - Intrahepatic cholangiocarcinoma: epidemiology, risk factors, diagnosis and surgical management JO - Cancer Lett VL - 379 UR - https://doi.org/10.1016/j.canlet.2015.09.008 DO - 10.1016/j.canlet.2015.09.008 ID - Zhang2016 ER - TY - JOUR AU - Le, D. T. AU - Durham, J. N. AU - Smith, K. N. AU - Wang, H. AU - Bartlett, B. R. AU - Aulakh, L. K. PY - 2017 DA - 2017// TI - Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade JO - Science VL - 357 UR - https://doi.org/10.1126/science.aan6733 DO - 10.1126/science.aan6733 ID - Le2017 ER - TY - JOUR AU - Abou-Alfa, G. K. AU - Sahai, V. AU - Hollebecque, A. AU - Vaccaro, G. AU - Melisi, D. AU - Al-Rajabi, R. PY - 2020 DA - 2020// TI - Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study JO - Lancet Oncol. VL - 21 UR - https://doi.org/10.1016/S1470-2045(20)30109-1 DO - 10.1016/S1470-2045(20)30109-1 ID - Abou-Alfa2020 ER - TY - JOUR AU - Friedman, A. A. AU - Letai, A. AU - Fisher, D. E. AU - Flaherty, K. T. PY - 2015 DA - 2015// TI - Precision medicine for cancer with next-generation functional diagnostics JO - Nat Rev Cancer VL - 15 UR - https://doi.org/10.1038/nrc4015 DO - 10.1038/nrc4015 ID - Friedman2015 ER - TY - JOUR AU - Chen, S. AU - Zhou, Y. AU - Chen, Y. AU - Gu, J. PY - 2018 DA - 2018// TI - Fastp: an ultra-fast all-in-one FASTQ preprocessor JO - Bioinformatics VL - 34 UR - https://doi.org/10.1093/bioinformatics/bty560 DO - 10.1093/bioinformatics/bty560 ID - Chen2018 ER - TY - JOUR AU - Li, H. AU - Durbin, R. PY - 2009 DA - 2009// TI - Fast and accurate short read alignment with Burrows-Wheeler transform JO - Bioinformatics VL - 25 UR - https://doi.org/10.1093/bioinformatics/btp324 DO - 10.1093/bioinformatics/btp324 ID - Li2009 ER - TY - JOUR AU - Chen, S. AU - Zhou, Y. AU - Chen, Y. AU - Huang, T. AU - Liao, W. AU - Xu, Y. PY - 2019 DA - 2019// TI - Gencore: an efficient tool to generate consensus reads for error suppressing and duplicate removing of NGS data JO - BMC Bioinform VL - 20 UR - https://doi.org/10.1186/s12859-019-3280-9 DO - 10.1186/s12859-019-3280-9 ID - Chen2019 ER - TY - JOUR AU - Li, H. AU - Handsaker, B. AU - Wysoker, A. AU - Fennell, T. AU - Ruan, J. AU - Homer, N. PY - 2009 DA - 2009// TI - The sequence alignment/map format and SAMtools JO - Bioinformatics VL - 25 UR - https://doi.org/10.1093/bioinformatics/btp352 DO - 10.1093/bioinformatics/btp352 ID - Li2009 ER - TY - JOUR AU - Wang, K. AU - Li, M. AU - Hakonarson, H. PY - 2010 DA - 2010// TI - ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data JO - Nucleic Acids Res VL - 38 UR - https://doi.org/10.1093/nar/gkq603 DO - 10.1093/nar/gkq603 ID - Wang2010 ER - TY - JOUR AU - Lowery, M. A. AU - Ptashkin, R. AU - Jordan, E. AU - Berger, M. F. AU - Zehir, A. AU - Capanu, M. PY - 2018 DA - 2018// TI - Comprehensive molecular profiling of intrahepatic and extrahepatic cholangiocarcinomas: potential targets for intervention JO - Clin Cancer Res VL - 24 UR - https://doi.org/10.1158/1078-0432.CCR-18-0078 DO - 10.1158/1078-0432.CCR-18-0078 ID - Lowery2018 ER - TY - JOUR AU - Valle, J. W. AU - Lamarca, A. AU - Goyal, L. AU - Barriuso, J. AU - Zhu, A. X. PY - 2017 DA - 2017// TI - New horizons for precision medicine in biliary tract cancers JO - Cancer Discov VL - 7 UR - https://doi.org/10.1158/2159-8290.CD-17-0245 DO - 10.1158/2159-8290.CD-17-0245 ID - Valle2017 ER - TY - JOUR AU - Galdy, S. AU - Lamarca, A. AU - McNamara, M. G. AU - Hubner, R. A. AU - Cella, C. A. AU - Fazio, N. PY - 2017 DA - 2017// TI - HER2/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target? JO - Cancer Metastasis Rev VL - 36 UR - https://doi.org/10.1007/s10555-016-9645-x DO - 10.1007/s10555-016-9645-x ID - Galdy2017 ER - TY - JOUR AU - Golan, T. AU - Raitses-Gurevich, M. AU - Kelley, R. K. AU - Bocobo, A. G. AU - Borgida, A. AU - Shroff, R. T. PY - 2017 DA - 2017// TI - Overall survival and clinical characteristics of BRCA-associated cholangiocarcinoma: a multicenter retrospective study JO - Oncologist. VL - 22 UR - https://doi.org/10.1634/theoncologist.2016-0415 DO - 10.1634/theoncologist.2016-0415 ID - Golan2017 ER - TY - JOUR AU - Sulkowski, P. L. AU - Corso, C. D. AU - Robinson, N. D. AU - Scanlon, S. AU - Purshouse, K. R. AU - Bai, H. PY - 2017 DA - 2017// TI - 2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity JO - Sci Transl Med. VL - 9 UR - https://doi.org/10.1126/scitranslmed.aal2463 DO - 10.1126/scitranslmed.aal2463 ID - Sulkowski2017 ER - TY - JOUR AU - Lee, J. AU - Park, S. H. AU - Chang, H. M. AU - Kim, J. S. AU - Choi, H. J. AU - Lee, M. A. PY - 2012 DA - 2012// TI - Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study JO - Lancet Oncol. VL - 13 UR - https://doi.org/10.1016/S1470-2045(11)70301-1 DO - 10.1016/S1470-2045(11)70301-1 ID - Lee2012 ER - TY - JOUR AU - Malka, D. AU - Cervera, P. AU - Foulon, S. AU - Trarbach, T. AU - Fouchardière, C. AU - Boucher, E. PY - 2014 DA - 2014// TI - Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 Trial JO - Lancet Oncol. VL - 15 UR - https://doi.org/10.1016/S1470-2045(14)70212-8 DO - 10.1016/S1470-2045(14)70212-8 ID - Malka2014 ER - TY - JOUR AU - Borbath, I. AU - Ceratti, A. AU - Verslype, C. AU - Demols, A. AU - Delaunoit, T. AU - Laurent, S. PY - 2013 DA - 2013// TI - Combination of gemcitabine and cetuximab in patients with advanced cholangiocarcinoma: a phase II study of the Belgian Group of Digestive Oncology JO - Ann Oncol VL - 24 UR - https://doi.org/10.1093/annonc/mdt337 DO - 10.1093/annonc/mdt337 ID - Borbath2013 ER - TY - JOUR AU - Jensen, L. H. AU - Lindebjerg, J. AU - Ploen, J. AU - Hansen, T. F. AU - Jakobsen, A. PY - 2012 DA - 2012// TI - Phase II marker-driven trial of panitumumab and chemotherapy in KRAS wild-type biliary tract cancer JO - Ann Oncol VL - 23 UR - https://doi.org/10.1093/annonc/mds008 DO - 10.1093/annonc/mds008 ID - Jensen2012 ER - TY - JOUR AU - Zhu, A. X. AU - Meyerhardt, J. A. AU - Blaszkowsky, L. S. AU - Kambadakone, A. R. AU - Muzikansky, A. AU - Zheng, H. PY - 2010 DA - 2010// TI - Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study JO - Lancet Oncol. VL - 11 UR - https://doi.org/10.1016/S1470-2045(09)70333-X DO - 10.1016/S1470-2045(09)70333-X ID - Zhu2010 ER - TY - JOUR AU - Iyer, R. V. AU - Pokuri, V. K. AU - Groman, A. AU - Ma, W. W. AU - Malhotra, U. AU - Iancu, D. M. PY - 2018 DA - 2018// TI - A multicenter phase II study of gemcitabine, capecitabine, and bevacizumab for locally advanced or metastatic biliary tract cancer JO - Am J Clin Oncol VL - 41 UR - https://doi.org/10.1097/COC.0000000000000347 DO - 10.1097/COC.0000000000000347 ID - Iyer2018 ER - TY - JOUR AU - Bréchon, M. AU - Dior, M. AU - Dréanic, J. AU - Brieau, B. AU - Guillaumot, M. A. AU - Brezault, C. PY - 2018 DA - 2018// TI - Addition of an antiangiogenic therapy, bevacizumab, to gemcitabine plus oxaliplatin improves survival in advanced biliary tract cancers JO - Invest New Drugs VL - 36 UR - https://doi.org/10.1007/s10637-017-0492-6 DO - 10.1007/s10637-017-0492-6 ID - Bréchon2018 ER - TY - JOUR AU - Uji, M. AU - Mizuno, T. AU - Ebata, T. AU - Sugawara, G. AU - Igami, T. AU - Uehara, K. PY - 2016 DA - 2016// TI - A case of advanced intrahepatic cholangiocarcinoma accidentally, but successfully, treated with capecitabine plus oxaliplatin (CAPOX) therapy combined with bevacizumab: a case report JO - Surg Case Rep. VL - 2 UR - https://doi.org/10.1186/s40792-016-0191-0 DO - 10.1186/s40792-016-0191-0 ID - Uji2016 ER - TY - JOUR AU - Chen, X. AU - Zhao, F. AU - Chen, D. AU - Yang, P. AU - Zhong, W. AU - Xu, X. PY - 2018 DA - 2018// TI - Successful treatment of colorectal liver metastasis harboring intrahepatic cholangiocarcinoma: a case report JO - Medicine VL - 97 UR - https://doi.org/10.1097/MD.0000000000013751 DO - 10.1097/MD.0000000000013751 ID - Chen2018 ER - TY - JOUR AU - Winkelmann, R. AU - Schneider, M. AU - Hartmann, S. AU - Schnitzbauer, A. A. AU - Zeuzem, S. AU - Peveling-Oberhag, J. PY - 2018 DA - 2018// TI - Microsatellite instability occurs rarely in patients with cholangiocarcinoma: a retrospective study from a German tertiary care hospital JO - Int J Mol Sci VL - 19 UR - https://doi.org/10.3390/ijms19051421 DO - 10.3390/ijms19051421 ID - Winkelmann2018 ER - TY - JOUR AU - Silva, V. W. AU - Askan, G. AU - Daniel, T. D. AU - Lowery, M. AU - Klimstra, D. S. AU - Abou-Alfa, G. K. PY - 2016 DA - 2016// TI - Biliary carcinomas: pathology and the role of DNA mismatch repair deficiency JO - Chin Clin Oncol. VL - 5 UR - https://doi.org/10.21037/cco.2016.10.04 DO - 10.21037/cco.2016.10.04 ID - Silva2016 ER - TY - JOUR AU - Le, D. T. AU - Uram, J. N. AU - Wang, H. AU - Bartlett, B. R. AU - Kemberling, H. AU - Eyring, A. D. PY - 2015 DA - 2015// TI - PD-1 Blockade in Tumors with Mismatch-Repair Deficiency JO - N Engl J Med VL - 372 UR - https://doi.org/10.1056/NEJMoa1500596 DO - 10.1056/NEJMoa1500596 ID - Le2015 ER - TY - JOUR AU - Goyal, L. AU - Zheng, H. AU - Yurgelun, M. B. AU - Abrams, T. A. AU - Allen, J. N. AU - Cleary, J. M. PY - 2017 DA - 2017// TI - A phase II and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma JO - Cancer VL - 123 UR - https://doi.org/10.1002/cncr.30571 DO - 10.1002/cncr.30571 ID - Goyal2017 ER - TY - JOUR AU - Kessler, E. R. AU - Eckhardt, S. G. AU - Pitts, T. M. AU - Bradshaw-Pierce, E. L. AU - O’byrant, C. L. AU - Messersmith, W. A. PY - 2016 DA - 2016// TI - Phase I trial of vandetanib in combination with gemcitabine and capecitabine in patients with advanced solid tumors with an expanded cohort in pancreatic and biliary cancers JO - Invest New Drugs. VL - 34 UR - https://doi.org/10.1007/s10637-015-0316-5 DO - 10.1007/s10637-015-0316-5 ID - Kessler2016 ER - TY - JOUR AU - El-Khoueiry, A. B. AU - Rankin, C. J. AU - Ben-Josef, E. AU - Lenz, H. AU - Gold, P. J. AU - Hamilton, R. D. PY - 2012 DA - 2012// TI - SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma JO - Invest New Drugs VL - 30 UR - https://doi.org/10.1007/s10637-011-9719-0 DO - 10.1007/s10637-011-9719-0 ID - El-Khoueiry2012 ER - TY - JOUR AU - Moehler, M. AU - Maderer, A. AU - Ehrlich, A. AU - Foerster, F. AU - Schad, A. AU - Nickolay, T. PY - 2019 DA - 2019// TI - Safety and efficacy of afatinib as add-on to standard therapy of gemcitabine/cisplatin in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, phase I trial with an extensive biomarker program JO - BMC Cancer. VL - 19 UR - https://doi.org/10.1186/s12885-018-5223-7 DO - 10.1186/s12885-018-5223-7 ID - Moehler2019 ER - TY - JOUR AU - Valle, J. W. AU - Wasan, H. AU - Lopes, A. AU - Backen, A. C. AU - Palmer, D. H. AU - Morris, K. PY - 2015 DA - 2015// TI - Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial JO - Lancet Oncol. VL - 16 UR - https://doi.org/10.1016/S1470-2045(15)00139-4 DO - 10.1016/S1470-2045(15)00139-4 ID - Valle2015 ER - TY - JOUR AU - Shroff, R. T. AU - Yarchoan, M. AU - O’Connor, A. AU - Gallagher, D. AU - Zahurak, M. L. AU - Rosner, G. PY - 2017 DA - 2017// TI - The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma JO - Br J Cancer VL - 116 UR - https://doi.org/10.1038/bjc.2017.119 DO - 10.1038/bjc.2017.119 ID - Shroff2017 ER - TY - JOUR AU - Churi, C. R. AU - Shroff, R. AU - Wang, Y. AU - Rashid, A. AU - Kang, H. C. AU - Weatherly, J. PY - 2014 DA - 2014// TI - Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications JO - PLoS ONE VL - 9 UR - https://doi.org/10.1371/journal.pone.0115383 DO - 10.1371/journal.pone.0115383 ID - Churi2014 ER - TY - JOUR AU - Ross, J. S. AU - Wang, K. AU - Gay, L. AU - Al-Rohil, R. AU - Rand, J. V. AU - Jones, D. M. PY - 2014 DA - 2014// TI - New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing JO - Oncologist. VL - 19 UR - https://doi.org/10.1634/theoncologist.2013-0352 DO - 10.1634/theoncologist.2013-0352 ID - Ross2014 ER - TY - JOUR AU - Zou, S. AU - Li, J. AU - Zhou, H. AU - Frech, C. AU - Jiang, X. AU - Chu, J. S. PY - 2014 DA - 2014// TI - Mutational landscape of intrahepatic cholangiocarcinoma JO - Nat Commun. VL - 5 UR - https://doi.org/10.1038/ncomms6696 DO - 10.1038/ncomms6696 ID - Zou2014 ER -